Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia - PubMed (original) (raw)

. 2002 May 15;99(10):3742-7.

doi: 10.1182/blood.v99.10.3742.

Affiliations

• PMID: 11986231
• DOI: 10.1182/blood.v99.10.3742

Free article

Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia

Rainer Hubmann et al. Blood. 2002.

Free article

Abstract

Members of the Notch family encode transmembrane receptors that modulate differentiation, proliferation, and apoptotic programs of many precursor cells, including hematopoietic progenitors. Stimulation of Notch causes cleavage followed by translocation of the intracellular domain (NotchIC) to the nucleus, where it activates transcription of CBF1 responsive genes. The aim of this study was to elucidate the mechanisms leading to the overexpression of CD23, a striking feature of B-cell chronic lymphocytic leukemia (B-CLL) cells. By electrophoretic mobility shift assays, we identified a transcription factor complex (C1) that binds sequence specific to one known and 4 newly identified putative CBF1 recognition sites in the CD23a core promoter region. With the use of Epstein-Barr virus (EBV)-infected B cells as a model for CBF1 mediated CD23a expression, C1 was found to be EBV inducible. Supershift assays revealed that the nuclear form of Notch2 is a component of C1 in B-CLL cells, supporting a model in which NotchIC activates transcription by binding to CBF1 tethered to DNA. Transient transfection of REH pre-B cells with an activated form of Notch2 induced endogenous CD23a, confirming that CD23a is a target gene of Notch2 signaling. Finally, reverse transcription-polymerase chain reaction and kinetic analysis demonstrated that the Notch2 oncogene is not only overexpressed in B-CLL cells but might also be related to the failure of apoptosis characteristic for this disease. In conclusion, these data suggest that deregulation of Notch2 signaling is involved in the aberrant expression of CD23 in B-CLL.

PubMed Disclaimer

Similar articles

• Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
  Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Duechler M, et al. Leukemia. 2005 Feb;19(2):260-7. doi: 10.1038/sj.leu.2403592. Leukemia. 2005. PMID: 15565166
• EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
  Ling PD, Hsieh JJ, Ruf IK, Rawlins DR, Hayward SD. Ling PD, et al. J Virol. 1994 Sep;68(9):5375-83. doi: 10.1128/JVI.68.9.5375-5383.1994. J Virol. 1994. PMID: 8057421 Free PMC article.
• Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation.
  Hsieh JJ, Nofziger DE, Weinmaster G, Hayward SD. Hsieh JJ, et al. J Virol. 1997 Mar;71(3):1938-45. doi: 10.1128/JVI.71.3.1938-1945.1997. J Virol. 1997. PMID: 9032325 Free PMC article.
• Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.
  Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M. Schwarzmeier JD, et al. Leuk Lymphoma. 2005 Feb;46(2):157-65. doi: 10.1080/10428190400010742. Leuk Lymphoma. 2005. PMID: 15621797 Review.
• CD23 and chronic lymphocytic leukemia.
  Sarfati M. Sarfati M. Blood Cells. 1993;19(3):591-6; discussion 597-9. Blood Cells. 1993. PMID: 8018941 Review.

Cited by

• Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.
  Zare H, Bashashati A, Kridel R, Aghaeepour N, Haffari G, Connors JM, Gascoyne RD, Gupta A, Brinkman RR, Weng AP. Zare H, et al. Am J Clin Pathol. 2012 Jan;137(1):75-85. doi: 10.1309/AJCPMMLQ67YOMGEW. Am J Clin Pathol. 2012. PMID: 22180480 Free PMC article.
• Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium.
  Kiaris H, Politi K, Grimm LM, Szabolcs M, Fisher P, Efstratiadis A, Artavanis-Tsakonas S. Kiaris H, et al. Am J Pathol. 2004 Aug;165(2):695-705. doi: 10.1016/S0002-9440(10)63333-0. Am J Pathol. 2004. PMID: 15277242 Free PMC article.
• Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
  Nefedova Y, Gabrilovich D. Nefedova Y, et al. Drug Resist Updat. 2008 Dec;11(6):210-8. doi: 10.1016/j.drup.2008.09.002. Epub 2008 Oct 31. Drug Resist Updat. 2008. PMID: 18951834 Free PMC article. Review.
• Notch signaling drives multiple myeloma induced osteoclastogenesis.
  Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R. Colombo M, et al. Oncotarget. 2014 Nov 15;5(21):10393-406. doi: 10.18632/oncotarget.2084. Oncotarget. 2014. PMID: 25257302 Free PMC article.
• Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening.
  Platonova N, Parravicini C, Sensi C, Paoli A, Colombo M, Neri A, Eberini I, Chiaramonte R. Platonova N, et al. PLoS One. 2017 Nov 3;12(11):e0182640. doi: 10.1371/journal.pone.0182640. eCollection 2017. PLoS One. 2017. PMID: 29099834 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal